Keros Therapeutics (NASDAQ:KROS - Free Report) had its target price reduced by HC Wainwright from $40.00 to $25.00 in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.
A number of other brokerages also recently issued reports on KROS. Piper Sandler decreased their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Wedbush restated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Tuesday, April 1st. Guggenheim reiterated a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Finally, Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research note on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.67.
View Our Latest Analysis on KROS
Keros Therapeutics Stock Performance
Shares of KROS traded down $0.37 during midday trading on Thursday, hitting $13.65. The company had a trading volume of 546,340 shares, compared to its average volume of 823,532. The company's 50-day simple moving average is $12.20 and its 200-day simple moving average is $24.47. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $72.37. The firm has a market capitalization of $554.39 million, a P/E ratio of -2.62 and a beta of 1.32.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period in the prior year, the firm posted ($1.21) EPS. Equities analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.
Insider Activity at Keros Therapeutics
In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was acquired at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 20.60% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of KROS. Vanguard Group Inc. grew its stake in shares of Keros Therapeutics by 31.1% during the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock worth $26,151,000 after purchasing an additional 609,212 shares during the period. XTX Topco Ltd purchased a new stake in Keros Therapeutics during the first quarter worth about $490,000. Federated Hermes Inc. grew its position in Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock worth $12,474,000 after buying an additional 1,099,519 shares during the period. Corton Capital Inc. purchased a new position in Keros Therapeutics in the first quarter valued at about $186,000. Finally, CWM LLC lifted its position in shares of Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after acquiring an additional 2,641 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
